Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gilteritinib versus salvage chemotherapy in relapsed/refractory FLT3-mutated AML
NCT02421939Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Oct 2015
- Primary completion
- Sep 2018
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 14
01
Overview
Phase 3, randomised, open-label trial of gilteritinib in acute myeloid leukemia (AML) (2 arms), sponsored by Astellas Pharma. Primary endpoints: Overall Survival and Complete Remission and Complete Remission With Partial Hematological Recovery. Started Oct 2015; status: completed.
02
Drugs
gilteritinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02421939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02421939.